Thermo Fisher Scientific (NYSE:TMO) Sets New 12-Month High – Here’s What Happened

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $710.84 and last traded at $707.4220, with a volume of 232,237 shares changing hands. The stock had previously closed at $693.02.

Analysts Set New Price Targets

Several analysts have commented on TMO shares. Stifel Nicolaus upped their price objective on Thermo Fisher Scientific from $650.00 to $775.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Guggenheim assumed coverage on Thermo Fisher Scientific in a research note on Thursday, October 15th. They issued a “buy” rating on the stock. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Royal Bank Of Canada boosted their price target on Thermo Fisher Scientific from $580.00 to $730.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 22nd. Finally, Barclays upped their price target on Thermo Fisher Scientific from $750.00 to $775.00 and gave the stock an “overweight” rating in a report on Thursday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $681.00.

View Our Latest Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Performance

The business has a fifty day simple moving average of $649.32 and a 200 day simple moving average of $551.60. The stock has a market cap of $259.60 billion, a price-to-earnings ratio of 37.03 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. The firm had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the firm earned $5.79 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.23 EPS for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 275 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,368 shares of company stock valued at $43,896,820 over the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TMO. BlackRock Inc. acquired a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $15,501,867,000. Corient Private Wealth LP acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth about $382,547,000. Bank of New York Mellon Corp purchased a new position in Thermo Fisher Scientific in the second quarter valued at about $1,974,561,000. Bank of America Corp DE purchased a new position in Thermo Fisher Scientific in the second quarter valued at about $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Thermo Fisher Scientific by 0.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock valued at $1,239,625,000 after purchasing an additional 22,827 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.

Featured Articles

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.